Get Support

Learn Mode

EXEL - Exelixis Inc

96

$42.89

$0.94 (2.241%)

At market close

$42.91

$0.02 (0.054%)

After Hours 3/31/26, 9:29 PM

4.41/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

EXEL

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$11.14B

Industry

Biotechnology

EPS (TTM)

$2.83

P/E (TTM)

14.23

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

4.80

P/B

5.15

Diluted Shares

276.35M

Ex-Dividend

--

Next Earnings

05-11

Forward P/E

12.73

Payout Ratio

--

P/FCF (TTM)

12.72

FCF Yield

7.86%

Earnings Yield

7.03%

52 Week Range

Score Card

Explore Scores Tab

4.41

Very Good

Exelixis Inc has grown revenue at 6.98% over the past year, which suggests sales are increasing. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

5.00

Very Good

Management

4.00

Good

Growth

5.00

Very Good

Profitability

2.00

Bad

Fin. Health

4.00

Good

Dividends

--

--

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 18:23:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-02 19:59:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-02 19:59:32

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-02 19:59:26

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-02 19:59:20

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-02 19:59:14

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 18:41:37

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-24 16:05:40

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 18:50:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-20 20:36:32

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-19 19:18:36

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-19 16:06:57

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$63.00

46.9%

Avg:

$47.77

11.4%

Low:

$35.35

-17.6%

(% change is relative to the current stock price: $42.89)

Analyst Recommendations

Go to Analyst Tab

3.74

Good

22%

Strong Buy (6)

33%

Buy (9)

41%

Hold (11)

4%

Sell (1)

0%

Strong Sell (0)

About

Website
https://www.exelixis.com/
Address
1851 Harbor Bay Parkway, Alameda CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=939767

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

IPO Date

2000-04-11

Industry

Biotechnology

Total Employees

1,147

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences